en · de · es · fr · pt
sr9009-notes.peptides5388.com › Faq › Analytical Detection And Stability — What the Evidence Shows

Analytical Detection And Stability — What the Evidence Shows

By Editorial Desk · published 2025-12-25 · last reviewed 2026-01-10 · Faq

If you have been reading about DMSO stock and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Sr9009 at a glance

PropertyValueNotes
Common synonymsSR9009; StenabolicNickname is not a chemical name.
Typical analytical methodLC-MS/MSOften with isotope-labeled internal standard.
Storage temperature-20 °CDesiccated and protected from light.
Solution stabilityDMSO stock; avoid freeze-thawStore at -20 to -80 °C.
Regulatory statusNot approved; varies by countryMay be restricted as research chemical.

Analytical and Handling Considerations

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

Related pages on this site

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Further detail

=== Challenges === Despite its promise, relatively little silk has reached the clinic, and the reasons are specific. Foremost among them is variability. Silk is a farmed natural product, so its composition shifts with the silkworm strain, its diet and its rearing conditions, and this batch-to-batch variation is difficult to reconcile with the strict specifications required of a medical device. Processing introduces further variation: the duration of exposure to the dissolving salt and the amount of heat applied both affect the molecular weight of the regenerated protein, and with it the strength and degradation of the final product. Sterilisation presents a further difficulty, since standard autoclaving alters the structure of the protein, and a gentler method must be identified and validated for each format. Controlling the degradation rate precisely, scaling laboratory processes to industrial volumes, and meeting the regulatory requirements for an implanted device are each demanding in their own right. These engineering and manufacturing obstacles, rather than any deficiency in the biological performance of silk, are the main reason that most of it remains in the laboratory.

Mister Donut has an orange and white logo in the likeness of a moustachioed chef. More recently, the chain developed a set of mascot characters based on its donuts. One character, "Pon de Lion" (ポン・デ・ライオン, Pon De Raion), a lion with a mane shaped like its "pon de ring" (ポン・デ・リング, Pon De Ringu) donut line, is used in Japan. In El Salvador, the mascots are five anthropomorphic doughnuts and a rooster that is used for the breakfast menu. The company uses the same logo as Japan, and the slogan is "La gran variedad" (The great variety).

For example, the International Brain Research Organization was founded in 1961, the International Society for Neurochemistry in 1963, the European Brain and Behaviour Society in 1968, and the Society for Neuroscience in 1969. Recently, the application of neuroscience research results has also given rise to applied disciplines as neuroeconomics, neuroeducation, neuroethics, and neurolaw. Over time, brain research has gone through philosophical, experimental, and theoretical phases, with work on neural implants and brain simulation predicted to be important in the future.

Colloquially, radioactive materials can be described as "hot," and non-radioactive materials can be described as "cold." There are instances in which cold iodide is administered to people in order to prevent the uptake of hot iodide by the thyroid gland. For example, blockage of thyroid iodine uptake with potassium iodide is used in nuclear medicine scintigraphy and therapy with some radioiodinated compounds that are not targeted to the thyroid, such as iobenguane (MIBG), which is used to image or treat neural tissue tumors, or iodinated fibrinogen, which is used in fibrinogen scans to investigate clotting. These compounds contain iodine, but not in the iodide form. However, since they may be ultimately metabolized or break down to radioactive iodide, it is common to administer non-radioactive potassium iodide to insure that metabolites of these radiopharmaceuticals is not sequestered by the thyroid gland and result in a concentrated radiation dose to that tissue. Potassium iodide has been distributed to populations exposed to nuclear fission accidents such as the Chernobyl disaster. The iodide solution SSKI, a saturated solution of potassium (K) iodide in water, has been used to block absorption of the radioiodine. Tablets containing potassium iodide are now also manufactured and stocked in central disaster sites by some governments for this purpose.

Sources: en.wikipedia.org

Supporting material

The two substrates of this enzyme are 5,10-methylenetetrahydrofolate and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 5,10-methenyltetrahydrofolate, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 5,10-methylenetetrahydrofolate:NAD+ oxidoreductase. This enzyme is also called methylenetetrahydrofolate dehydrogenase (NAD+). This enzyme participates in one carbon pool by folate.

== Cause == The cause of PAH is unknown. Idiopathic PAH (WHO group 1.1) is not associated with an underlying disease or exposure. It is estimated that 39-46% of those with PAH have the idiopathic variant. Group 1.2 PAH includes the variants that are heritable. Genetic variants or mutations in bone morphogenic protein receptor 2 (BMPR2) account for approximately 75-80% of cases of heritable PAH. BMPR2 mutations are also seen in 20% of idiopathic PAH. BMPR2 is a protein involved in endothelial cell (cells that line blood vessels) proliferation and remodeling. Other types of genes coding for proteins involved in BMPR2 signaling have also been implicated as causes of heritable PAH, such as activin A receptor type-2-like-1 ACVRL1, Endoglin (ENG), SMAD genes encoding for SMAD transcription factors involved in downstream BMPR2 signaling and cell growth including Smad1, Smad4 and Smad9. KCNK3 encodes for a potassium channel which regulates membrane potential across cells thus controlling vascular tone. Eukaryotic translation initiation factor 2 alpha kinase 4 (E1F2AK4) is mutated causes heritable pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Group 1.3 PAH includes disease that is due to drug or toxin exposures. Methamphetamines, the chemotherapeutic dasatinib and the appetite suppressant and diet drug fenfluramine are associated with PAH. Group 1.4 PAH is disease that is associated with underlying disease.

In the extreme case of performance-enhancing substances, athletes, particularly bodybuilders may choose to use illegal substances such as anabolic steroids. These compounds which are related to the hormone testosterone, can quickly build mass and strength, but have many adverse effects such as high blood pressure and negative gender specific effects. Blood doping, another illegal ergogenic, was discovered in the 1940s when it was used by World War II pilots. Blood doping also known as blood transfusions, increases oxygen delivery to exercising tissues and has been demonstrated to improve performance in endurance sports, such as long-distance cycling. Blood doping is banned by International Olympic Committee and other International Sport Authorities and Federations.

Atul Malhotra is the Vice Chair of Medicine for Research and Research Chief of pulmonary, critical care, sleep medicine, and physiology at the University of California, San Diego's Medical School. In addition, he is the Peter C. Farrell Presidential Chair and tenured professor of medicine at the same university. He is the author of almost 600 original research publications and over 300 reviews and book chapters.

=== Genetic testing === For some types of paediatric ILDs and few forms adult ILDs, genetic causes have been identified. These may be identified by blood tests. For a limited number of cases, this is a definite advantage, as a precise molecular diagnosis can be done; frequently then there is no need for a lung biopsy. Testing is available for

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 measured in samples?

The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.

What storage conditions are typical for SR9009?

Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network